CD34(+)CD19(-)CD22(+) B-cell progenitors may underlie phenotypic escape in patients treated with CD19-directed therapies

Autor: Bueno, C, Barrena, S, Bataller, A, Ortiz-Maldonado, V, Elliott, N, O'Byrne, S, Wang, G, Rovira, M, Gutierrez-Agüera, F, Trincado, JL, Gonzalez, M, Morgades, M, Sorigué, M, Barcena, P, Zanetti, SR, Torrebadell, M, Vega-García, N, Rives, S, Mallo, M, Sole, F, Mead, AJ, Roberts, I, Thongjuea, S, Psaila, B, Juan, M, Delgado, J, Urbano-Ispizua, Á, Ribera, J-M, Orfao, A, Roy, A, Menéndez, P

Publikováno v: Blood
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
Web of Science
r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu

CD19-directed immunotherapies have revolutionized the treatment of advanced B-cell acute lymphoblastic leukemia (B-ALL). Despite initial impressive rates of complete remission (CR) many patients ultimately relapse. Patients with B-ALL successfully tr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7a4137a8616f5462683ece52e9a144ac
https://fundanet.igtp.cat/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=6919

Immune cell profiling of the cerebrospinal fluid enables the characterization of the brain metastasis microenvironment

Autor: Paolo Nuciforo, Domenica Marchese, Carlota Rubio-Perez, Juan L. Trincado, Juan Sahuquillo, Josep Tabernero, Estela Pineda, Ester Bonfill-Teixidor, Holger Heyn, Francisco Martínez-Ricarte, Josep Maria Mesquida González, Genís Parra, Sara Ruiz, Leire Pedrosa, Marta Cicuendez, Joan Seoane, Catia Moutinho, Garazi Serna, Ester Planas-Rigol, Esteban Cordero, Laura Escudero, Alexandra Arias, Raffaella Iurlaro

Publikováno v: Nature Communications
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
Scientia
Nature Communications, Vol 12, Iss 1, Pp 1-10 (2021)

Brain metastases are the most common tumor of the brain with a dismal prognosis. A fraction of patients with brain metastasis benefit from treatment with immune checkpoint inhibitors (ICI) and the degree and phenotype of the immune cell infiltration

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c28146f5cc3842c28edd6973146420cd
http://hdl.handle.net/10230/47651

NG2 is a target gene of MLL-AF4 and underlies glucocorticoid resistance in MLLr B-ALL by regulating NR3C1 expression.

Autor: Lopez-Millan B; Stem Cell Biology, Developmental Leukemia and Immunotherapy Group, Josep Carreras Leukemia Research Institute, Barcelona, Spain.; GENYO, Centre for Genomics and Oncological Research, Pfizer/Universidad de Granada/Junta de Andalucía, Granada, Spain.; Department of Physiology, University of Granada, Granada, Spain.; Red Española de Terapias Avanzadas Network, Instituto de Salud Carlos III, Madrid, Spain., Rubio-Gayarre A; Stem Cell Biology, Developmental Leukemia and Immunotherapy Group, Josep Carreras Leukemia Research Institute, Barcelona, Spain.; GENYO, Centre for Genomics and Oncological Research, Pfizer/Universidad de Granada/Junta de Andalucía, Granada, Spain.; Red Española de Terapias Avanzadas Network, Instituto de Salud Carlos III, Madrid, Spain., Vinyoles M; Stem Cell Biology, Developmental Leukemia and Immunotherapy Group, Josep Carreras Leukemia Research Institute, Barcelona, Spain.; Red Española de Terapias Avanzadas Network, Instituto de Salud Carlos III, Madrid, Spain., Trincado JL; Stem Cell Biology, Developmental Leukemia and Immunotherapy Group, Josep Carreras Leukemia Research Institute, Barcelona, Spain., Fraga MF; Fundación para la Investigación Biosanitaria de Asturias, Instituto de Investigación Sanitaria del Principado de Asturias, Instituto Universitario de Oncología de Asturias, Hospital Universitario Central de Asturias, Universidad de Oviedo, Oviedo, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Raras, Instituto de Salud Carlos III, Oviedo, Spain.; Nanomaterials and Nanotechnology Research Center, Universidad de Oviedo, Oviedo, Spain., Fernandez-Fuentes N; Stem Cell Biology, Developmental Leukemia and Immunotherapy Group, Josep Carreras Leukemia Research Institute, Barcelona, Spain.; Red Española de Terapias Avanzadas Network, Instituto de Salud Carlos III, Madrid, Spain., Guerrero-Murillo M; Stem Cell Biology, Developmental Leukemia and Immunotherapy Group, Josep Carreras Leukemia Research Institute, Barcelona, Spain.; Red Española de Terapias Avanzadas Network, Instituto de Salud Carlos III, Madrid, Spain., Martinez A; Stem Cell Biology, Developmental Leukemia and Immunotherapy Group, Josep Carreras Leukemia Research Institute, Barcelona, Spain.; Red Española de Terapias Avanzadas Network, Instituto de Salud Carlos III, Madrid, Spain., Velasco-Hernandez T; Stem Cell Biology, Developmental Leukemia and Immunotherapy Group, Josep Carreras Leukemia Research Institute, Barcelona, Spain.; Red Española de Terapias Avanzadas Network, Instituto de Salud Carlos III, Madrid, Spain., Falgàs A; Stem Cell Biology, Developmental Leukemia and Immunotherapy Group, Josep Carreras Leukemia Research Institute, Barcelona, Spain.; Red Española de Terapias Avanzadas Network, Instituto de Salud Carlos III, Madrid, Spain., Panisello C; Stem Cell Biology, Developmental Leukemia and Immunotherapy Group, Josep Carreras Leukemia Research Institute, Barcelona, Spain.; Red Española de Terapias Avanzadas Network, Instituto de Salud Carlos III, Madrid, Spain., Valcarcel G; Epigenetic Control of Hematopoiesis Group, Josep Carreras Leukemia Research Institute, Barcelona, Spain., Sardina JL; Epigenetic Control of Hematopoiesis Group, Josep Carreras Leukemia Research Institute, Barcelona, Spain., López-Martí P; 3D Chromatin Organization Group, Josep Carreras Leukemia Research Institute, Barcelona, Spain., Javierre BM; 3D Chromatin Organization Group, Josep Carreras Leukemia Research Institute, Barcelona, Spain., Del Valle-Pérez B; Programa de Recerca en Càncer, Institut Hospital del Mar d'Investigacions Mèdiques, Unitat Associada al Consejo Superior de Investigaciones Científicas, Departament de Medicina i Ciències de la Vida, Universitat Pompeu Fabra, Barcelona, Spain., García de Herreros A; Programa de Recerca en Càncer, Institut Hospital del Mar d'Investigacions Mèdiques, Unitat Associada al Consejo Superior de Investigaciones Científicas, Departament de Medicina i Ciències de la Vida, Universitat Pompeu Fabra, Barcelona, Spain., Locatelli F; Department of Pediatric Hematology-Oncology, Istituto di Ricovero e Cura a Carattere Scientifico, Bambino Gesù Children's Hospital, Rome, Italy., Pieters R; Princess Màxima Center for Pediatric Oncology, Utrecht, The Netherlands., Bardini M; Tettamanti Center, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico San Gerardo dei Tintori, Monza, Italy., Cazzaniga G; Tettamanti Center, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico San Gerardo dei Tintori, Monza, Italy.; School of Medicine and Surgery, University of Milan Bicocca, Monza, Italy., Rodríguez-Manzaneque JC; GENYO, Centre for Genomics and Oncological Research, Pfizer/Universidad de Granada/Junta de Andalucía, Granada, Spain., Hanewald T; Institute of Pharmaceutical Biology/Diagnostic Center of Acute Leukemia, Goethe University of Frankfurt, Biocenter, Frankfurt/Main, Germany., Marschalek R; Institute of Pharmaceutical Biology/Diagnostic Center of Acute Leukemia, Goethe University of Frankfurt, Biocenter, Frankfurt/Main, Germany., Milne TA; Medical Research Council, Molecular Haematology Unit, Medical Research Council Weatherall Institute of Molecular Medicine, National Institute for Health and Care Research, Oxford Biomedical Research Center Hematology Theme, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom., Stam RW; Princess Màxima Center for Pediatric Oncology, Utrecht, The Netherlands., Tejedor JR; Fundación para la Investigación Biosanitaria de Asturias, Instituto de Investigación Sanitaria del Principado de Asturias, Instituto Universitario de Oncología de Asturias, Hospital Universitario Central de Asturias, Universidad de Oviedo, Oviedo, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Raras, Instituto de Salud Carlos III, Oviedo, Spain.; Nanomaterials and Nanotechnology Research Center, Universidad de Oviedo, Oviedo, Spain., Menendez P; Stem Cell Biology, Developmental Leukemia and Immunotherapy Group, Josep Carreras Leukemia Research Institute, Barcelona, Spain.; Red Española de Terapias Avanzadas Network, Instituto de Salud Carlos III, Madrid, Spain.; Department of Biomedicine, School of Medicine, University of Barcelona, Barcelona, Spain.; Centro de Investigación Biomédica en Red de Cáncer, Instituto de Salud Carlos III, Barcelona, Spain.; Instituciò Catalana de Recerca i Estudis Avançats, Barcelona, Spain., Bueno C; Stem Cell Biology, Developmental Leukemia and Immunotherapy Group, Josep Carreras Leukemia Research Institute, Barcelona, Spain.; Red Española de Terapias Avanzadas Network, Instituto de Salud Carlos III, Madrid, Spain.; Centro de Investigación Biomédica en Red de Cáncer, Instituto de Salud Carlos III, Barcelona, Spain.

Publikováno v: Blood [Blood] 2024 Nov 07; Vol. 144 (19), pp. 2002-2017.

Grass pollen allergoids conjugated with mannan for subcutaneous and sublingual immunotherapy: a dose-finding study.

Autor: Ojeda P; Clínica de Asma y Alergia Dres. Ojeda, Madrid, Spain., Barjau MC; Centro de Asma y Alergia Subiza, Madrid, Spain., Subiza J; Centro de Asma y Alergia Subiza, Madrid, Spain., Moreno A; Clínica Atlas, Aranjuez, Spain., Ojeda I; Clínica de Asma y Alergia Dres. Ojeda, Madrid, Spain., Solano E; Servicio de Alergia, Hospital Universitario Ramón y Cajal, Madrid, Spain., Alonso A; Clínica Alianza Médica, Valladolid, Spain., Caballero R; Inmunotek, Alcalá de Henares, Spain., Del Pozo S; Inmunotek, Alcalá de Henares, Spain.; Department of Medicine and Medical Specialities, Faculty of Medicine, University of Alcalá de Henares, Alcalá de Henares, Spain., Gómez-Perosanz M; Inmunotek, Alcalá de Henares, Spain.; Department of Immunology & O2, School of Medicine, University Complutense of Madrid, Madrid, Spain., Sánchez-Trincado JL; Department of Immunology & O2, School of Medicine, University Complutense of Madrid, Madrid, Spain., Benito-Villalvilla C; Department of Biochemistry and Molecular Biology, School of Chemistry, University Complutense of Madrid, Madrid, Spain., Angelina A; Department of Biochemistry and Molecular Biology, School of Chemistry, University Complutense of Madrid, Madrid, Spain., Soria I; Inmunotek, Alcalá de Henares, Spain., Reche PA; Department of Immunology & O2, School of Medicine, University Complutense of Madrid, Madrid, Spain., Palomares O; Department of Biochemistry and Molecular Biology, School of Chemistry, University Complutense of Madrid, Madrid, Spain., Subiza JL; Inmunotek, Alcalá de Henares, Spain., Casanovas M; Inmunotek, Alcalá de Henares, Spain.

Publikováno v: Frontiers in immunology [Front Immunol] 2024 Jun 26; Vol. 15, pp. 1431351. Date of Electronic Publication: 2024 Jun 26 (Print Publication: 2024).

Converging and evolving immuno-genomic routes toward immune escape in breast cancer.

Autor: Blanco-Heredia J; IrsiCaixa, Germans Trias i Pujol University Hospital, Badalona, Spain.; Germans Trias i Pujol Research Institute (IGTP), Badalona, Spain.; Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Souza CA; IrsiCaixa, Germans Trias i Pujol University Hospital, Badalona, Spain.; Germans Trias i Pujol Research Institute (IGTP), Badalona, Spain., Trincado JL; Centro Nacional de Análisis Genómico (CNAG), Barcelona, Spain.; Josep Carreras Leukemia Research Institute, Barcelona, Spain., Gonzalez-Cao M; Dexeus Institute of Oncology, Quironsalud Group, Barcelona, Spain., Gonçalves-Ribeiro S; Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital, Barcelona, Spain., Gil SR; Centro Nacional de Análisis Genómico (CNAG), Barcelona, Spain., Pravdyvets D; Omniscope, Barcelona, Spain., Cedeño S; IrsiCaixa, Germans Trias i Pujol University Hospital, Badalona, Spain., Callari M; Cancer Research UK Cambridge Institute, Robinson Way, Cambridge, UK., Marra A; Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Gazzo AM; Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Weigelt B; Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Pareja F; Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Vougiouklakis T; Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Jungbluth AA; Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Rosell R; Dexeus Institute of Oncology, Quironsalud Group, Barcelona, Spain., Brander C; IrsiCaixa, Germans Trias i Pujol University Hospital, Badalona, Spain.; ICREA, Passeig de Lluís Companys, 23, Barcelona, Spain.; Universitat de Vic-Universitat Central de Catalunya, Catalunya, Spain., Tresserra F; Dexeus Institute of Oncology, Quironsalud Group, Barcelona, Spain., Reis-Filho JS; Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Tiezzi DG; Department of Gynecology and Obstetrics - Breast Disease Division and Laboratory for Translational Data Science, Ribeirao Preto Medical School, University of Sao Paulo, Ribeirao Preto, Brazil.; Advanced Research Center in Medicine (CEPAM), Union of the Colleges of the Great Lakes (UNILAGO), São José do Rio Preto, Brazil., de la Iglesia N; IrsiCaixa, Germans Trias i Pujol University Hospital, Badalona, Spain., Heyn H; Centro Nacional de Análisis Genómico (CNAG), Barcelona, Spain.; Omniscope, Barcelona, Spain., De Mattos-Arruda L; IrsiCaixa, Germans Trias i Pujol University Hospital, Badalona, Spain. ldmarruda@gmail.com.; Germans Trias i Pujol Research Institute (IGTP), Badalona, Spain. ldmarruda@gmail.com.

Publikováno v: Nature communications [Nat Commun] 2024 Feb 21; Vol. 15 (1), pp. 1302. Date of Electronic Publication: 2024 Feb 21.